Drugs / CM512
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT06553209 | Sep 2024 → Aug 2025 | atopic eczema | Keymed Biosciences Co.Ltd | Completed | Met primary |
| Phase 27 trials | ||||||
| Phase 2 | NCT07519577 | May 2026 → May 2028 expected | chronic rhinosinusitis | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07230483 | Dec 2025 → Dec 2027 expected | atopic eczema | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07166211 | Nov 2025 → Nov 2026 expected | chronic idiopathic urticaria | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07011524 | Aug 2025 → Jul 2027 expected | asthma | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06980142 | Jun 2025 → Mar 2028 expected | chronic obstructive pulmonary disease | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06947980 | Jun 2025 → Jul 2026 overdue | atopic eczema | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06930612 | May 2025 → Sep 2026 overdue | chronic rhinosinusitis | Keymed Biosciences Co.Ltd | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-09-10 | Keymed Biosciences Co.Ltd | Results 康诺亚自主研发全球首款长效TSLP×IL-13双抗CM512治疗哮喘海外Ib期临床研究取得积极中期结果 keymedbio.com ↗
研究显示，CM512可快速、深度、持续降低FeNO及血嗜酸性粒细胞水平，并显著改善患者肺功能，验证了CM512在哮喘治疗中的临床价值及差异化潜力。 |
| 2026-07-23 | Keymed Biosciences Co.Ltd | Regulatory 康诺亚CM512纳入突破性治疗品种名单，全球首款长效TSLP x IL-13双抗临床开发再提速 keymedbio.com ↗
2026年7月23日，康诺亚（香港联交所代码：02162）宣布，公司自主研发的 全球首款长效TSLP x IL-13双阻断剂CM512被国家药品监督管理局药品审评中心（CDE）纳入突破性治疗品种名单，用于治疗慢性鼻窦炎伴鼻息肉 。 |
| 2025-11-04 | Keymed Biosciences Co.Ltd | Results 半衰期达70天！康诺亚TSLP x IL-13双抗CM512特应性皮炎I期临床研究结果公布 keymedbio.com ↗
2025年11月4日，康诺亚（2162.HK）宣布，公司自主研发的全球首款长效TSLP x IL-13双阻断剂CM512治疗成人中重度特应性皮炎（AD）I期临床研究（研究代号：CM512-100001）达成全部研究终点。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-10 | Keymed Biosciences Co.Ltd | 康诺亚自主研发全球首款长效TSLP×IL-13双抗CM512治疗哮喘海外Ib期临床研究取得积极中期结果 keymedbio.com ↗ |
| 2026-07-23 | Keymed Biosciences Co.Ltd | 康诺亚CM512纳入突破性治疗品种名单，全球首款长效TSLP x IL-13双抗临床开发再提速 keymedbio.com ↗ |
| 2025-11-04 | Keymed Biosciences Co.Ltd | 半衰期达70天！康诺亚TSLP x IL-13双抗CM512特应性皮炎I期临床研究结果公布 keymedbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07519577 ↗ |
| Action | Inhibit | “CM512 significantly reduced free TSLP and IL-13” PMID 42292382 ↗ May 2026 |
| Route | Subcutaneous | “subcutaneous CM512 or placebo per cohort” PMID 42292382 ↗ May 2026 |
| Target | TSLP | “CM512 is a novel recombinant bispecific antibody targeting both TSLP and IL-13 with high affinity.” PMID 42292382 ↗ May 2026 |